Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A

Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A

SSSE:600513
11.88
CNY
-0.31
(-2.54%)
4.31BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.31
2.52
2.27
2.12
2.44
3.6
4.53
4.84
5.68
6.78
7.57
7.44
- -
- -
Basic EPS, GAAP
0.14
0.17
0.18
0.22
0.25
0.26
0.28
0.36
0.41
0.49
0.47
0.29
- -
- -
Free Cash Flow per Basic Share
0.02
0.17
0.12
0.08
-0.16
-0.78
-0.63
-0.29
-0.11
-0.28
-0.14
-0.6
- -
- -
Dividend per Share
0.06
0.08
0.07
0.05
0.08
0.1
0.11
0.15
0.14
0.19
0.18
0.17
- -
0.19
Book Value per Share
1.52
1.64
2.71
2.9
3.08
3.26
3.43
3.72
4.02
4.41
4.74
4.89
- -
4.44
Tangible Book Value per Share
1.49
1.62
2.68
2.75
2.91
3.09
3.04
3.29
3.54
3.9
4.18
3.91
- -
2.26
Basic Weighted Avg Shares
270
266
283
285
282
283
285
286
290
289
287
290
285
294
Sales/Revenue/Turnover
623
669
642
605
689
1,019
1,290
1,386
1,646
1,955
2,174
2,160
- -
- -
Operating Margin (%)
8.1
8.57
9.21
11.78
12.88
8.94
8.71
11.77
10.89
11.23
9.11
6.64
- -
- -
Depreciation Expense
15
19
20
24
25
22
20
22
28
41
56
61
- -
- -
Net Income, GAAP
38
44
50
63
71
74
80
103
119
141
135
84
- -
- -
Effective Tax Rate (%)
16.27
17.12
17.49
18.99
21.53
15.55
17.95
15.36
12.32
11.96
13.54
18.41
- -
- -
Profit Margin (%)
6.15
6.58
7.8
10.36
10.24
7.22
6.18
7.43
7.22
7.23
6.21
3.9
- -
- -
Working Capital
185
189
494
575
583
407
282
239
185
125
107
138
- -
-43
LT Debt
- -
- -
- -
- -
20
- -
47
46
50
50
83
86
- -
510
Total Equity
402
434
775
827
878
947
1,084
1,182
1,281
1,414
1,517
1,577
- -
1,671
Return on Invested Capital (%)
7.65
8.2
6.88
6.93
7.42
7.34
6.83
8.35
8.34
8.61
7.09
4.6
- -
- -
Return on Capital (%)
8.62
9.51
7.91
7.42
7.74
7.53
6.81
6.83
6.92
7.21
6.63
3.51
- -
- -
Return on Common Equity (%)
9.84
10.53
8.3
7.83
8.28
8.14
8.31
10
10.66
11.66
10.3
6.12
- -
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,285
1,355
1,235
LT Borrowings
320
351
506
LT Finance Leases
5
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
285
285
285
Market Capitalization
7,981
4,151
4,308

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,981
2,014
1,915
Cash, Cash Equivalents & STI
266
286
228
Accounts Receivable, Net
737
713
692
Inventories
618
649
638
Total Current Liabilities
2,116
2,174
1,958
Payables & Accruals
- -
- -
- -
ST Debt
1,285
1,355
1,235
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
528
598
518
516
2,160
2025
628
658
- -
- -
- -
2026
811
760
757
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.11
0.1
-0.03
0.29
2025
0.08
-0.22
- -
- -
- -
2026
0.02
0.01
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.11
0.02
0.02
0.17
2025
0.02
0.08
- -
- -
- -
2026
0.05
0.01
0.13
- -
- -

Company Description

CEO
Ben Niu
Full Time Employees
2,131
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 9 Jiankangyi Road Yangzhou JS China 225127
IPO Date
Mar 19, 2003
Business
Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SS) engages in the research, development, production, and sale of pharmaceuticals in China, with operations encompassing pharmaceutical manufacturing and distribution; it manufactures chemical raw materials, injections, solid preparations, and other dosage forms across multiple therapeutic categories including urinary system drugs such as epristeride tablets and tadalafil tablets; antihistamines including ebastine tablets, bepotastine besilate tablets, and terfenadine tablets; cardiovascular drugs such as felodipine tablets, clopidogrel bisulfate tablets, and milrinone injection; steroidal hormones including danazol capsules and suppositories; antibiotics such as azithromycin tablets, doxycycline hydrochloride tablets, and moxifloxacin hydrochloride tablets; and additional products like dapoxetine hydrochloride tablets for premature ejaculation, abiraterone acetate tablets for cancer treatment, sertraline hydrochloride capsules, temozolomide capsules, and metformin glipizide tablets. The company also wholesales chemical raw materials and pharmaceuticals, sells medical equipment and electronic products, and provides medical technology research, development, and transfer services; its products export to Southeast Asia, North America, South America, Europe, New Zealand, Australia, and other regions. Founded in 1999 by the Yangzhou Pharmaceutical Factory established in 1958 and listed on the Shanghai Stock Exchange in 2003, Jiangsu Lianhuan Pharmaceutical is headquartered in Yangzhou, Jiangsu Province, China, and holds national high-tech enterprise status with multiple provincial honors. Recent developments include selection in 2023 as one of the first world-class professional leading demonstration enterprises in Jiangsu and the only local state-owned enterprise in its city to receive this recognition; in 2025, its wholly-owned subsidiary acquired a 54% stake in Xinxiang Changle Pharmaceutical for nearly 202 million yuan to expand capabilities; strategic cooperation agreements signed in September 2025 by subsidiaries including Yangzhou Lianhuan Investment and Nanjing Lianzhi Pharmaceutical Technology with Chengdu Yazhong Biopharmaceutical to advance cardiovascular R&D and market transformation; regulatory approval in September 2025 for famotidine injection; a planned 15 million yuan investment announced in November 2024 for joint antithrombotic drug R&D with Nanjing University; multiple capital increases in 2025 totaling over 140 million yuan to subsidiaries like Yangzhou Lianhuan Investment and Lianhuan (Anqing) to support strategic expansion despite ongoing losses in those units; and successive approvals for generic drugs targeting respiratory systems amid rising R&D expenses.